Mitchell J Frederick

9PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 06, 2025
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.

Pedram Yadollahi, Kelli A McCord, Yang Li

|Jul 31, 2025
Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.

Rutulkumar Patel, Kalil Saab, Lixia Luo

|Jan 27, 2025
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting.

P Yadollahi, K A McCord, Y Li

|Oct 11, 2023
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.

Phillip M Pifer, Liangpeng Yang, Manish Kumar

|Apr 03, 2023
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.

Wangie Yu, Yunyun Chen, Nagireddy Putluri

|Jan 23, 2023
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.

Abdullah A Osman, Emre Arslan, Mason Bartels

Pageof 2